Evidence map›Paper›PMID 38637144›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024

Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [

Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 47 citations in OpenAlex.

  1. Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. Patient Survival and Its Relation to Tumor Absorbed Dose in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Predicting tumour and organ dose in α-radiopharmaceutical therapy: aEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  5. Review
  6. Dosimetry inJournal of clinical medicine · 2026
    Review
  7. Review
  8. Article
  9. Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  14. Review
  15. Substantial decrease in tumor dose over subsequent cyles of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  16. Article
  17. Review
  18. Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  19. Organ and tumour dosimetry ofEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  20. Establishing In Vitro Dosimetric Models and Dose-Effect Relationships forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Kévin HebertDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Lore SantoroDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Maeva MonnierBiometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Florence CastanBiometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Ikrame BerkaneDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Eric AssénatDepartment of Medical Oncology, CHU de Montpellier, Université de Montpellier, Montpellier, France.
Cyril FersingDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Pauline GélibertCentre Hospitalier Métropole Savoie, Chambéry, France.
Jean-Pierre PougetInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France.
Manuel BardièsDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Pierre-Olivier KotzkiDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France.
Emmanuel DeshayesDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France; emmanuel.deshayes@icm.unicancer.fr.
Université de Montpellier · FRInstitut de Recherche en Cancérologie de Montpellier · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Métropole Savoie · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[

Indexed as

Dose-Response Relationship, RadiationIntestinal NeoplasmsNeuroendocrine TumorsOctreotideOrganometallic CompoundsPancreatic NeoplasmsPrecision MedicineRadiometryStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle Agedlutetium Lu 177 dotatateOctreotideOrganometallic Compounds[177Lu]Lu-DOTATATEabsorbed dose–response relationshipneuroendocrine tumors

Identifiers

PMID38637144
PMCPMC11149595
OpenAlexW4394910364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.